How Lumbrokinase Works
Lumbrokinase is not a single enzyme but a mixture of at least six serine proteases — enzymes that break apart proteins by cleaving specific peptide bonds. When taken orally in enteric-coated capsules (which protect the enzymes through the acidic stomach environment), these compounds are absorbed and exert cardiovascular effects through several distinct pathways [3].
Fibrinolysis and fibrinogen reduction: Lumbrokinase directly degrades fibrin clots and cleaves circulating fibrinogen. Elevated fibrinogen is an independent risk factor for cardiovascular events, and lowering it mechanically addresses one root cause of thrombotic disease [1][2].
Antiplatelet activity: Ji et al. found that lumbrokinase raises cyclic AMP (cAMP) levels inside platelets. cAMP is a signaling molecule that keeps platelets in a relaxed, non-aggregating state — similar to the mechanism of some pharmaceutical antiplatelet drugs [3].
Anti-inflammatory effects: Lumbrokinase inhibits ICAM-1 (intercellular adhesion molecule-1), a protein that helps inflammatory white blood cells attach to blood vessel walls. By reducing this adhesion, it may slow the inflammatory cascade that contributes to atherosclerosis [3].
Neuroprotection: During ischemic events (when blood flow is cut off to the brain), cells die through an apoptosis pathway involving JAK1/STAT1 signaling. Lumbrokinase activates JAK1/STAT1 in a way that suppresses apoptosis, helping neurons survive oxygen deprivation [3].
Cardioprotection via Sirt1: A separate pathway involves Sirt1, a deacetylase enzyme associated with stress resistance and longevity. Post-ischemic treatment with lumbrokinase activates Sirt1 in heart tissue, reducing ventricular arrhythmias and limiting infarct size after a cardiac ischemic event [5].
ER stress modulation: In ischemic neurons, endoplasmic reticulum (ER) stress — a form of cellular distress triggered when the protein-folding machinery is overwhelmed — drives much of the cell death. Lumbrokinase reduces ER stress markers and improves neurological outcomes in stroke models [6].
Dosage and Form
Lumbrokinase supplements are typically sold in enteric-coated capsules to preserve enzyme activity through the stomach. Potency is measured in SPU (serrapeptase unit equivalents), with products ranging from 200,000 to 600,000 SPU per capsule. Research protocols have generally used 2–3 capsules daily taken on an empty stomach for maximum absorption. The supplement brand Boluoke (Canada RNA Biochemical Inc.) has been used in several published studies.
Who Uses It
In China and East Asia, lumbrokinase has been prescribed in clinical settings for stroke rehabilitation and blood viscosity management for decades. Western use has grown among integrative cardiologists and functional medicine practitioners, particularly for patients with elevated fibrinogen, thick blood, or history of thrombotic events who prefer non-pharmaceutical approaches.
Important Cautions
Because lumbrokinase reduces clotting, it should not be combined with blood-thinning medications (warfarin, aspirin, heparin, dabigatran, rivaroxaban, or similar drugs) without medical supervision. Additive effects could significantly increase bleeding risk. People scheduled for surgery should discontinue it at least one to two weeks beforehand.
See our nattokinase page for another well-researched natural fibrinolytic enzyme, and our serrapeptase page for a third enzyme in this class.
Evidence Review
Research on lumbrokinase spans in vitro mechanistic work, animal models, small clinical trials, and at least one multicenter RCT, with the bulk of human data originating from Chinese clinical medicine.
Multicenter RCT for secondary stroke prevention (Cao et al., 2013): The highest-quality human evidence comes from a multicenter, randomized, parallel-group controlled trial published in the Chinese Medical Journal [1]. Patients who had experienced a prior ischemic stroke received lumbrokinase or standard care. The lumbrokinase group showed significant reductions in plasma fibrinogen — a well-established biomarker of thrombotic risk — compared to controls. The study design (multicenter, parallel group, randomized) represents the strongest evidence tier for clinical trials.
Cerebral infarction and coagulation pathway changes (Jin et al., 2000): Jin et al. measured specific coagulation markers before and after lumbrokinase treatment in cerebral infarction patients [2]. Treatment reduced activity in the intrinsic coagulation cascade (which drives clot initiation) while increasing tissue plasminogen activator (t-PA) — the body's own clot-dissolving enzyme — effectively shifting the blood from a pro-clotting to a pro-fibrinolytic state. This mechanistic confirmation in human subjects helps explain why lumbrokinase produces the clinical outcomes observed in stroke trials.
Comprehensive mechanistic analysis (Ji et al., 2008): This European Journal of Pharmacology study provided the most detailed mechanistic portrait, demonstrating three simultaneous protective mechanisms in a cerebral ischemia model [3]: (1) antiplatelet effects through cAMP elevation in platelets; (2) anti-inflammatory effects through ICAM-1 inhibition, reducing leukocyte adhesion to vessel endothelium; and (3) neuroprotective anti-apoptotic effects via JAK1/STAT1 signaling. The convergence of three independent mechanisms makes lumbrokinase mechanistically distinctive compared to single-target anticoagulants.
Myocardial perfusion in stable angina (Kasim et al., 2009): A Malaysian pilot study published in the Journal of Alternative and Complementary Medicine enrolled 42 patients with stable angina who were already on standard cardiac therapy [4]. After 30 days of oral lumbrokinase added to their regimen, patients underwent nuclear myocardial perfusion imaging — an objective test of blood flow to the heart muscle. The lumbrokinase group showed measurable improvements in myocardial perfusion compared to those continuing standard therapy alone. Though the sample size limits conclusions, the use of objective imaging rather than self-reported symptoms strengthens the finding.
Cardioprotection via Sirt1 activation (Wang et al., 2018): This Frontiers in Pharmacology study moved beyond fibrinolysis to identify a cardioprotective mechanism acting on the heart muscle itself [5]. Post-ischemic lumbrokinase treatment in animal models activated Sirt1 — a deacetylase enzyme involved in cellular stress resistance — in cardiac tissue. This activation reduced the incidence and severity of ventricular arrhythmias following ischemia-reperfusion and limited the size of infarcted (dead) tissue. The Sirt1 pathway is a target of active longevity research and is distinct from lumbrokinase's fibrinolytic mechanisms, suggesting the enzyme's cardiovascular benefits are multifaceted.
ER stress and neurological recovery in stroke (Wang et al., 2022): The same Taiwanese research group published a follow-up study in Neuropharmacology showing that lumbrokinase reduces endoplasmic reticulum (ER) stress in ischemic brain tissue [6]. ER stress — the accumulation of misfolded proteins within the ER — is a key trigger of neuronal death in stroke. By modulating ER stress pathways, lumbrokinase treatment improved neurological deficits in ischemic stroke models, adding a third neuroprotective mechanism alongside the JAK/STAT anti-apoptotic and direct fibrinolytic pathways documented in earlier work.
Strength of evidence: The evidence base is most robust for stroke-related indications, particularly secondary prevention and acute cerebral infarction treatment, where human clinical trials converge with mechanistic studies. The coronary artery disease data (angina) rests on a single small pilot study and warrants cautious interpretation. Almost all clinical data originate from East Asian medical centers, and independent replication in Western populations is limited. The mechanistic research (multiple pathways, multiple laboratories) provides strong biological plausibility. Overall assessment: promising and mechanistically coherent, with adequate clinical evidence for stroke-related applications and early-stage evidence for broader cardiovascular benefit. Independent large-scale trials are needed to establish optimal dosing and confirm efficacy across diverse populations.